Who Exports Nivolumab from India — 23 Suppliers Behind a $2.3M Market
India's nivolumab export market is supplied by 23 active exporters who collectively shipped $2.3M across 144 shipments. DR.REDDY'S LABORATORIES LTD leads with a 25.3% market share, followed by CORSANTRUM TECHNOLOGY and VAMA LIFECARE PRIVATE LIMITED. The top 5 suppliers together control 36.0% of total export value, reflecting a moderately competitive market structure.
Top Nivolumab Exporters from India — Ranked by Export Value
DR.REDDY'S LABORATORIES LTD is the leading nivolumab exporter from India, holding a 25.3% share of the $2.3M market across 144 shipments from 23 exporters. The top 5 suppliers — DR.REDDY'S LABORATORIES LTD, CORSANTRUM TECHNOLOGY, VAMA LIFECARE PRIVATE LIMITED, MODERN DRUG HOUSE, SPECIALITY MEDICINES LIMITED — collectively control 36.0% of total export value, indicating a competitive market. Individual shares are: DR.REDDY'S LABORATORIES LTD (25.3%), CORSANTRUM TECHNOLOGY (5.0%), VAMA LIFECARE PRIVATE LIMITED (3.2%), MODERN DRUG HOUSE (1.3%), SPECIALITY MEDICINES LIMITED (1.3%).
Top Nivolumab Exporters from India
Ranked by export value · 23 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | DR.REDDY'S LABORATORIES LTD NIVOLUMAB 100MG/10ML-FOR TESTING PURPOSEONLYNIVOLUMAB 100MG 10ML FOR TESTING PURPOSEONLYNIVOLUMAB 40MG/4ML-FOR TESTING PURPOSE ONLY | $577.4K | 5 | 25.3% |
| 2 | CORSANTRUM TECHNOLOGY HARMLESS MEDICINE FOR HUMAN CONSUMPTIONNIVOLUMAB 100MGOPDIVO 100MG INJECTION EACH TABLET CONTAINS NIVOLUMAB | $115.1K | 1 | 5.0% |
| 3 | VAMA LIFECARE PRIVATE LIMITED HARMLESS MEDICINE FOR HUMAN CONSUMPTIONNIVOLUMAB 100MGOPDIVO 100MG INJECTION EACH TABLET CONTAINS NIVOLUMAB | $72.9K | 1 | 3.2% |
| 4 | MODERN DRUG HOUSE | $28.7K | 1 | 1.3% |
| 5 | SPECIALITY MEDICINES LIMITED HARMLESS MEDICINE FOR HUMAN CONSUMPTIONNIVOLUMAB 100MGOPDIVO 100MG INJECTION EACH TABLET CONTAINS NIVOLUMAB | $28.6K | 1 | 1.3% |
| 6 | RBN MEDITECH PRIVATE LIMITED HARMLESS MEDICINE FOR HUMAN CONSUMPTIONNIVOLUMAB 100MGOPDIVO 100MG INJECTION EACH TABLET CONTAINS NIVOLUMAB | $28.4K | 1 | 1.2% |
| 7 | VEA IMPEX I PRIVATE LIMITED OPDYTA 100 MG NIVOLUMAB 100 MGOPDYTA 40 MG INJ NIVOLUMABOPDYTA 100MG INJ NIVOLUMAB | $27.9K | 3 | 1.2% |
| 8 | SPECIALITY MEDICINES PRIVATE LIMITED HARMLESS MEDICINE FOR HUMAN CONSUMPTIONNIVOLUMAB 100MGOPDIVO 100MG INJECTION EACH TABLET CONTAINS NIVOLUMAB | $27.8K | 1 | 1.2% |
| 9 | MEDIX OPDYTA 40 MG INJ NIVOLUMABOPDYTA 100MG INJ NIVOLUMABNIVOLUMAB - INJECTIONS - 100MG - OPDYTA | $27.0K | 1 | 1.2% |
| 10 | NU HOSPITALS PRIVATE LIMITED OPDYTA 40 MG INJ NIVOLUMABOPDYTA 100MG INJ NIVOLUMABNIVOLUMAB - INJECTIONS - 100MG - OPDYTA | $12.0K | 1 | 0.5% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Nivolumab exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Dr. Reddy's Laboratories Ltd | Approved | Yes | Yes | Not verified | FDA issued a warning letter on November 5, 2015, for cGMP violations; the letter |
TransData Nexus reviewed the regulatory standing of 1 leading Nivolumab exporters from India. 1 hold US FDA facility approvals, 1 maintain WHO-GMP certification, and 1 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Nivolumab sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of active pharmaceutical ingredients (APIs). The city hosts numerous API manufacturers, including Neuland Laboratories, which specializes in the development and production of APIs and advanced intermediates. The presence of such companies underscores Hyderabad's critical role in supplying essential components for biologics like Nivolumab.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Ahmedabad-based Zydus Lifesciences has recently launched Tishtha™, the world's first biosimilar of Nivolumab, marking a significant advancement in oncology treatments. This development highlights the region's capability in producing complex biologics and biosimilars, contributing to both domestic healthcare and export markets.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for Indian pharmaceuticals. Mumbai, being the financial capital, houses numerous pharmaceutical companies with extensive export operations. The region's well-established infrastructure and proximity to major ports facilitate the efficient export of pharmaceuticals, including Nivolumab, to international markets.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives. This area attracts numerous pharmaceutical companies, contributing to the production capacity for various drugs. While specific data on Nivolumab production in this region is limited, the overall manufacturing capabilities support the broader pharmaceutical supply chain.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the technical expertise and regulatory compliance of suppliers, especially for complex biologics like Nivolumab.
- Monitor Regulatory Developments: Stay informed about changes in tax incentives and regulatory policies that may impact manufacturing and export activities in these clusters.
- Leverage Export Infrastructure: Utilize the established export channels in regions like Mumbai-Thane-Raigad to ensure efficient distribution to international markets.
By strategically sourcing from these specialized clusters, companies can enhance the reliability and efficiency of their Nivolumab supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Nivolumab exporters from India
Dr. Reddy's Laboratories Ltd. — Dr. Reddy's acquires Nimbus Health GmbH
Dr. Reddy's Laboratories Ltd. acquired Nimbus Health GmbH, a German pharmaceutical company, expanding its footprint in the European market. - IMPACT: This acquisition is expected to enhance Dr. Reddy's distribution network in Europe, potentially increasing Nivolumab exports to the region.
Impact: This acquisition is expected to enhance Dr. Reddy's distribution network in Europe, potentially increasing Nivolumab exports to the region.
Dr. Reddy's Laboratories Ltd. — Dr. Reddy's merges with Dr. Reddy's Holdings Limited
Dr. Reddy's Laboratories Ltd. completed the merger with its subsidiary, Dr. Reddy's Holdings Limited, consolidating its operations and streamlining corporate structure. - IMPACT: The merger is anticipated to improve operational efficiency, potentially leading to increased production and export capacity for Nivolumab.
Impact: The merger is anticipated to improve operational efficiency, potentially leading to increased production and export capacity for Nivolumab.
Dr. Reddy's Laboratories Ltd. — Dr. Reddy's merges with Dr. Reddy's Laboratories LLC, Russia
Dr. Reddy's Laboratories Ltd. merged with its Russian subsidiary, Dr. Reddy's Laboratories LLC, to strengthen its presence in the Russian market. - IMPACT: This merger is likely to bolster Dr. Reddy's market share in Russia, a key destination for Nivolumab exports, thereby potentially increasing export volumes.
Impact: This merger is likely to bolster Dr. Reddy's market share in Russia, a key destination for Nivolumab exports, thereby potentially increasing export volumes.
Common Questions — Nivolumab Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which nivolumab supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, DR.REDDY'S LABORATORIES LTD leads with 15 recorded shipments worth $577.4K. CORSANTRUM TECHNOLOGY (22 shipments) and VAMA LIFECARE PRIVATE LIMITED (7 shipments) are also established high-volume exporters.
Q How many nivolumab manufacturers are there in India?
India has 23 active nivolumab exporters with a combined export market of $2.3M across 144 shipments to 13 countries. The top 5 suppliers hold 36.0% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for nivolumab from India?
Average FOB unit price: $583.34 per unit, ranging from $0.71 to $1824.74. Average shipment value: $15.9K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 23 verified Indian exporters of Nivolumab ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 144 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 13 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
144 Verified Shipments
23 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists